The API5 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of HeLa cervical carcinoma epithelial cells engineered to disrupt the apoptosis inhibitor 5 (API5) gene. This pooled knockout approach generates a heterogeneous loss-of-function model, enabling robust analysis of API5-dependent phenotypes across a diverse genetic background. The polyclonal format avoids clonal artifacts, providing a physiologically relevant system for studying apoptosis regulation and oncogenic signaling.
HeLa cells are an immortalized human cervical adenocarcinoma line harboring human papillomavirus type 18 (HPV18) sequences and displaying adherent epithelial morphology. Widely employed in cancer research, virology, and drug screening, HeLa cells offer a well-characterized platform for investigating molecular mechanisms underlying cervical carcinogenesis. Their rapid proliferation and robust experimental tractability make them ideal for high-content functional genomics studies.
API5 is a multifunctional protein that suppresses apoptosis primarily through direct interaction with procaspase-9, preventing its activation and subsequent caspase cascade. Additionally, API5 modulates E2F1 transcriptional activity, influencing cell cycle progression and survival gene expression. Its role in mRNA export, involving interactions with nucleoporins NUP98 and RAE1, further links API5 to proliferative signaling. Upstream, API5 is regulated by transcription factors including E2F1, NF-??B, and MYC, as well as growth factors such as EGF and FGF. Downstream, API5 orchestrates expression of BCL2 family members, matrix metalloproteinases, and cyclin D1/CDK4, integrating signals from the PI3K/AKT and NF-??B pathways to promote cell survival and oncogenic transformation.
In the HeLa cell context, API5 knockout is particularly significant given its established overexpression in cervical cancer and other malignancies, including breast, non-small cell lung, hepatocellular, and ovarian carcinomas. Disruption of API5 in this HPV18-positive cervical adenocarcinoma model permits detailed dissection of apoptosis resistance mechanisms and identification of synthetic lethal interactions. This model provides a powerful tool for evaluating the dependency of cervical cancer cells on API5-mediated survival pathways and for investigating crosstalk between viral oncoproteins and anti-apoptotic signaling.
This API5 knockout polyclonal cell population supports a broad range of research applications, including quantitative assessment of caspase-9 activation, mitochondrial outer membrane permeabilization, and downstream apoptotic markers via western blotting and flow cytometry. Proliferation and viability assays (MTT, BrdU) enable analysis of API5-dependent growth, while cell cycle analysis and migration/invasion assays furnish insights into its role in tumor progression. The model is also suitable for drug sensitivity screening (IC50 determination), RNA-seq transcriptomic profiling, co-immunoprecipitation of API5 interaction partners such as NUP98 and TIP60, and immunofluorescence localization studies. For further details, please contact Ascent Research.
